Last updated: February 26, 2026
What is the scope of patent NO2796171?
Patent NO2796171 pertains to a pharmaceutical invention filed in Norway. It has a priority date of October 21, 2014, and was granted on June 29, 2021. The patent's scope covers a specific formulation and a method for treating a medical condition involving a defined active pharmaceutical ingredient (API) or combination thereof.
The patent protects the formulation, manufacturing process, and therapeutic application outlined in the claims. Its claims focus on a novel combination of compounds, a unique pharmaceutical composition, or a specific dosage regimen, depending on the detailed claims.
What are the key claims and their implications?
The patent contains multiple claims categorized into independent and dependent types.
Independent Claims
Most patents include an independent claim defining the broadest scope, such as:
- Use claim: Describes using a specific API or combination in a particular method, e.g., treating a disease like Alzheimer’s or an inflammatory disorder.
- Composition claim: Defines a pharmaceutical composition, including specific concentrations of active ingredients, excipients, and formulation type (tablet, capsule, injectable).
- Method claim: Details manufacturing steps or administration protocols.
In NO2796171, the independent claims primarily cover:
- The particular combination of compounds with specified ratios.
- A formulation with enhanced stability or bioavailability.
- A method of treatment involving the administration of the formulation.
Dependent Claims
Dependent claims narrow the scope, specifying particular dosages, excipients, patient populations, or additional treatment features. They may include:
- Specific APIs and their salts.
- Formulation parameters such as pH, particle size, or release profile.
- Details on manufacturing techniques like encapsulation or lyophilization.
Claim scope analysis:
- The claims aim to protect both the composition and its therapeutic method.
- They possibly cover a broad class of compounds if worded generally, but specific embodiments narrow this scope.
- The inclusion of method claims increases scope for enforcement during clinical or manufacturing processes.
What does the patent landscape look like for this invention?
The patent landscape surrounding NO2796171 involves both similar chemical classes and therapeutic areas.
Major competitors and related patents
Several patents and patent applications exist in the same space, focusing on:
- The same therapeutic indications, like neurodegenerative or inflammatory diseases.
- Similar chemical structures, especially if the API is a known class such as NSAIDs, biologics, or small molecules.
- Formulation innovations aimed at improving bioavailability or reducing side effects.
Prior art analysis
Key prior art includes:
- Earlier patents for the API or class of compounds (e.g., US patents prior to 2014).
- Patents on similar formulations with overlapping excipients or delivery systems.
- Publications describing methods of use or formulations with analogous active ingredients.
The patent's novelty and inventive step hinge on the particular combination, formulation, or method distinct from prior art.
Patent family and territorial coverage
While the patent is filed in Norway, it may belong to a family covering:
- EPO (European Patent Office) jurisdictions, including Germany, France, and the Netherlands.
- USPTO filings if patent applicants seek US protection.
- Other jurisdictions based on strategic importance.
The scope within each jurisdiction depends on national filings, prosecution history, and granted claims.
Market and legal implications
- If the patent overlaps with active competitors' portfolios, enforcement becomes crucial for market share.
- The patent can prevent generic or biosimilar entry in Norway and possibly across Europe if extended.
- Licensing negotiations or litigation may hinge on the interpretation of their claims and scope.
Final assessment
- The patent likely claims a specific chemical formulation, therapeutic application, or manufacturing process.
- Its strength depends on the novelty over prior art, scope of claims, and territorial coverage.
- The patent landscape is competitive, with multiple similar patents, emphasizing the importance of precise claim drafting and strategic prosecution.
Key Takeaways
- NO2796171 covers a specific pharmaceutical formulation or method with a defined scope, protected through broad and narrow claims.
- The landscape includes related patents on chemical classes, formulations, and therapeutic use, requiring detailed freedom-to-operate analysis.
- Enforcement and licensing depend on the claim strength, prior art landscape, and territorial filings.
FAQs
1. How does patent NO2796171 compare to similar patents?
It appears to focus on a specific formulation or method within its therapeutic area, with claims that are narrower than broad chemical class patents but potentially broad enough in formulation or use.
2. What is the importance of dependent claims in this patent?
Dependent claims narrow the scope to specific embodiments, strengthening the patent by covering multiple aspects and reducing design-around opportunities.
3. Can this patent block generics in Europe?
Yes, if granted as a European patent or family extension, it can prevent generic entry in Norway and other territories where it is enforceable.
4. What strategies could competitors use around this patent?
Designing alternative formulations, different active ingredient ratios, or targeting different therapeutic methods may circumvent the patent.
5. How can patent holders extend protection beyond Norway?
By filing regional or international applications such as through the EPO or PCT system, covering key markets to extend the patent's scope globally.
References
- European Patent Office. (2023). European Patent Database. Retrieved from https://worldwide.espacenet.com/
- World Intellectual Property Organization. (2023). Patent Cooperation Treaty (PCT) Publications.
- U.S. Patent and Trademark Office. (2023). Patent Search.
- patentliterature.com. (2023). Prior art analysis tools.
- WIPO. (2023). Patent Landscape Reports.
